What Cyclo Progynova Treats: Main Uses and Benefits

Cyclo Progynova is applied in addressing the symptoms related to estrogen deficiency, a condition characterized by systemic imbalance. The medication is commonly used to help with symptoms related to the climacteric phase (menopause), and is applicable across domains where additional symptomatic support is needed. These applications include the prominent vasomotor symptoms (hot flashes and night sweats), alongside neuro-psychological disturbances (e.g., mood swings and sleep problems), and symptoms related to irritative states, such as vaginal dryness. It is also used in settings where additional symptomatic assistance is needed, such as for the prevention of postmenopausal osteoporosis in high-risk women and is applied in addressing primary or secondary amenorrhea to help achieve a predictable bleeding pattern.

This supportive approach contributes to easing the overall symptom load. It assists with maintaining functional stability and supports general well-being during symptomatic phases.

“This application offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, particularly during phases when symptoms become more noticeable.”

---

Quick Fact: Relief for Vasomotor and Localized Symptoms This sequential combined HRT provides support that helps ease the overall symptom burden. It supports the patient during difficult episodes by easing distress related to both systemic and localized discomforts.

Who Can and Cannot Use Cyclo Progynova

Cyclo Progynova's eligibility profile is strictly defined by governmental regulatory documentation, identifying the populations who are allowed to use the medicine and those who are absolutely excluded.

The medicine is primarily intended for postmenopausal and perimenopausal women with an intact uterus. Use is conditional and determined by patient health status and age.

It is contraindicated and must not be used by patients with a known or suspected history of breast cancer or other sex hormone-dependent malignancies. Absolute contraindications also include previous or existing venous thromboembolic events (DVT or PE), severe liver disease or liver tumours, undiagnosed vaginal bleeding, and severe hypertriglyceridaemia.

Eligibility Status	Key Regulatory Rule
Contraindicated	Pregnancy and Breastfeeding; Children and adolescents under 18 years (use is not indicated)
Conditional Use	Patients with hypertension, diabetes mellitus, endometriosis, or a history of endometrial hyperplasia require close monitoring

Use has not been specifically studied in patients with renal impairment, though no dose adjustment is typically required. These official statements confine the drug's use to a specific adult profile, as determined by regulatory authorities.

Interactions with Other Medicines and Products

The official interaction profile for Cyclo Progynova is defined by pharmacokinetic changes involving the metabolism and systemic clearance of the active hormones, Estradiol valerate and Norgestrel. These interactions are categorized as follows:

Classification	Interacting Substances	Interaction Outcome (as per Label)
Enzyme Inducers	Rifampicin, Carbamazepine, Phenytoin, Barbiturates	Reduces Exposure of hormones via induction of CYP3A4 and UGT enzymes, increasing clearance.
Enzyme Inhibitors	Azole Antifungals (e.g., Ketoconazole, Itraconazole), Macrolide Antibiotics	Increases Exposure of hormones via inhibition of CYP3A4, reducing clearance.
Perpetrator Effect	Combined Hormones (Estrogen Component)	Reduces Plasma Levels and increases the clearance of co-administered drugs like Lamotrigine through UGT induction.

Co-administration with enzyme inducers, including the herbal product St. John's Wort (Hypericum perforatum), is restricted as it significantly decreases the systemic concentration of the hormones. Furthermore, the estrogen component can raise the concentration of binding globulins, which may necessitate an adjustment in the dose of replacement thyroid hormone or cortisol therapy. Excessive intake of alcohol is also officially noted to have an influence on the overall treatment context.

Cyclo Progynova contains the pro-drug estradiol valerate and the synthetic progestogen norgestrel. Following oral administration, estradiol valerate is rapidly hydrolyzed by plasma and liver esterases to release the biologically active 17beta-estradiol.

17beta-Estradiol functions as an agonist at the nuclear estrogen receptor (ER), including ERalpha and ERbeta subtypes, which are present in numerous tissues such as bone, liver, and reproductive organs like the uterus. Upon binding, the activated ER dimerizes and translocates to the nucleus, binding to specific DNA sequences known as Estrogen Response Elements (EREs). This interaction modulates the transcription of target genes, leading to systemic physiological effects.

Norgestrel acts as a synthetic progestogen, exhibiting agonist activity primarily at the nuclear progesterone receptor (PR) in target tissues, notably the endometrium. Activation of the PR by norgestrel leads to a transcriptional cascade that induces glandular atrophy and stromal decidualization within the endometrium. This PR agonism is a counter-regulatory mechanism intended to oppose the estrogen-induced proliferative effects on endometrial tissue, preventing unchecked growth.

How to Use Cyclo Progynova

The usage of Cyclo Progynova is based on a fixed, sequential administration schedule that utilizes two different tablet types over a 28-day cycle. The route of administration is oral, with one tablet taken daily. The lowest effective dose should be used for the shortest possible duration of treatment.

---

Administration Protocol

The regimen is structured as a 21-day active tablet intake followed by a 7-day break, maintaining a consistent start day for each subsequent pack.

Instruction	Detail
Route of Administration	Oral (swallowing the sugar-coated tablets whole with liquid).
Dosing Schedule	One tablet daily as part of the fixed sequential combined regimen.
Daily Timing	Tablets should be taken at approximately the same time every day.

---

Official Use Sequence and Rules

Treatment initiation depends on the patient's hormonal status. Women who are still menstruating typically begin treatment on the 5th day of the cycle. Patients with no periods or those who are postmenopausal may start taking the medication immediately after excluding pregnancy.

The fixed sequential cycle is as follows:

• Estrogen-only Phase: One white tablet (2 mg Estradiol valerate) daily for the first 11 consecutive days.
• Combined Phase: One light brown tablet (2 mg Estradiol valerate and 0.5 mg Norgestrel) daily for the subsequent 10 consecutive days.
• Break: Follow the 21 days of active tablets with a 7-day tablet-free interval.

Handling of Missed Doses

If the scheduled dose is forgotten, it should be taken as soon as possible, provided less than 24 hours have elapsed. If more than 24 hours have passed, the missed tablet must not be taken, and the user should continue with the next scheduled tablet at the regular time. A delay of more than 24 hours may increase the likelihood of irregular bleeding.

No dose adjustment is required for older adults, but the medicine is not indicated for patients under 18 years of age.

Research Evidence / Overview of Studies for Cyclo Progynova

Evidence for Hormone Replacement Therapy (HRT) for Menopausal Symptoms

Research examining Cyclo Progynova included studies on populations with conditions characterized by fluctuating or episodic manifestations of menopausal symptoms, and has primarily involved Randomized Controlled Trials (RCTs) and longer-term observational studies. These studies were mostly conducted in healthy postmenopausal women and were designed to explore short-term symptom changes over defined time intervals. Researchers examined outcomes related to physical discomfort, such as hot flashes and night sweats, using measurements of symptom intensity or variability, which are considered patient-reported outcomes describing perceived discomfort. Research also examined measurements of changes in bone mineral density over the course of the research.

Studies monitored these populations and reported measurements of symptom evolution in the observed groups during the study period. Findings described patterns observed in the studies related to changes in the measurements of menopausal symptom scores. Studies also reported data related to bone mineral density over time in the population studied. These study results reflect the specific conditions under which they were conducted and contribute to the broader evidence landscape regarding treatment patterns.

Evidence for Treatment of Primary or Secondary Amenorrhea

Studies explored populations with conditions marked by functional limitations such as primary or secondary amenorrhea. Research in this area relies more heavily on smaller clinical trials and structured case analyses. Researchers examined outcomes related to hormonal status, primarily monitoring for the establishment of a withdrawal bleed and observing changes in hormonal markers.

Studies conducted during periods of temporary physiological imbalance reported measurements of hormonal biomarker shifts and described the frequency of menstrual-like bleeding during the course of the research. Findings indicate soft, non-causal patterns related to the monitored physiological changes. The sample sizes were modest in many of these investigations, and findings describe group patterns, not personal outcomes.

What is Still Uncertain About Cyclo Progynova Research

Comparative evidence against a wide range of other HRT products is limited in the available research, as many studies focus on comparing the product to a placebo. Evidence quality varies across studies, leading to mixed findings in certain areas. Furthermore, long-term effects are not fully established for this specific combination, meaning that while research highlights what is known, there is limited information for long-term outcomes and durability of effects. The research provides context but not individual predictions, and certainty remains low in areas where data for certain groups remain insufficient. Research is ongoing to address these gaps.

Key Studies & References

1. Cyclo-Progynova - coated tablets estradiol valerate/norgestrel - Patient Information Leaflet (PIL) used for regulatory context
2. Guideline No. 422a: Menopause: Vasomotor Symptoms, Prescription Therapeutic Agents, Complementary and Alternative Medicine, Nutr - SOGC (Used for HRT clinical context and treatment goals)
3. HRT Guidance and Treatment Pathway - NHS (Used for long-term and premature menopause HRT guidance and study context)

Common questions about Cyclo Progynova (FAQ)

---

Q: What is the main purpose of the combination of hormones in Cyclo Progynova?

According to official product information, the combination of hormones is designed to replace hormones no longer produced by the ovaries, which helps to alleviate common menopausal symptoms. Regulatory documents also state that the medicine is used for the treatment of missing, missed, too frequent, too rare, or irregular menstrual periods resulting from hormonal imbalances.

---

Q: Is Cyclo Progynova a type of birth control or contraceptive?

Cyclo Progynova is officially classified as a Hormone Replacement Therapy (HRT) product used solely for the purpose of hormone supplementation. The official classification as HRT indicates that it is not intended to be used for the purpose of contraception.

---

Q: What are the general expectations for a woman's menstrual pattern while taking this medicine?

When the medicine is taken regularly, the composition and effect are designed to establish a cyclical pattern similar to a normal menstrual cycle. This means that a withdrawal bleed is typically expected during the tablet-free interval of the regimen.

---

Q: What types of skin changes, like dryness or peeling, have been reported in users?

Official safety information documents list various skin changes reported by users. These may include a rash, itching, eczema, or acne. Less common effects include unusual hair loss or hair growth, and increased skin pigmentation, particularly on the face (a condition known as chloasma).

---

Q: What visual disturbances are listed in the official safety information for this drug?

Visual disturbances are listed among the possible adverse effects in official documents. These may include a sudden impairment of perception or vision disorders, such as double vision. In rare or severe cases, partial or complete loss of vision has been noted.

---

Q: Is there a listed side effect related to dizziness or vertigo?

Dizziness is addressed in official documents in two ways. It is listed as a symptom of estrogen deficiency that the medicine is used to alleviate. However, dizziness is also listed as a possible adverse effect that some individuals may experience during treatment.

---

Q: Does Cyclo Progynova carry an increased risk of gallbladder issues?

Official safety information indicates that the use of oral hormone replacement therapies, including this medicine, may be associated with an increased risk of gallbladder disease. For individuals who already have gallstones (Cholelithiasis), this condition is listed as one that requires close supervision during treatment.

---

Q: Is there a stated link between Cyclo Progynova and mood changes or depression?

Mood changes, anxiety, and depressive symptoms are listed in official documents as possible outcomes. Like dizziness, these are listed both as climacteric symptoms that the medicine is used to help alleviate and as possible adverse effects that may be experienced during treatment.

---

Q: What is the official guidance on using Cyclo Progynova for women who have a history of endometriosis?

Official guidance indicates that patients with a history of endometriosis or uterine fibroids are subject to close supervision during the therapy. This is because these conditions may potentially recur or be aggravated by hormone treatment.

---

Q: Are there specific warnings for women with diabetes who take Cyclo Progynova?

Official regulatory documents indicate that patients with Diabetes mellitus (with or without vascular involvement) require close supervision during the course of treatment.

---

Q: Does a history of severe high blood pressure affect eligibility for this medication?

Official guidance indicates that patients with hypertension are subject to close supervision during treatment. Regulatory documents state that a significant increase in blood pressure is officially listed as a reason for immediate withdrawal of therapy.

---

Q: How is Cyclo Progynova different from the medicine Progynova, which contains only estrogen?

The key difference is that Cyclo Progynova is a combination product containing two hormones: an estrogen and a progestogen. Progynova contains only an estrogen. The progestogen component in Cyclo Progynova is strategically included to oppose the estrogen's proliferative effect on the uterine lining and is necessary for women with an intact uterus.

---

Q: What is the difference between 'sequenced' and 'continuous' HRT regimens?

A sequential (cyclical) regimen, like Cyclo Progynova, involves taking a progestogen for a limited number of days in the cycle, followed by a tablet-free break. A continuous regimen, in contrast, involves taking both hormones every day without a break, which typically results in no cyclical bleeding.

---

Q: Is there a known interaction between Cyclo Progynova and thyroid medication like Levothyroxine?

The estrogen component in the medicine can increase the concentration of certain binding globulins in the body. This effect may necessitate an adjustment in the dose of replacement thyroid hormone, such as Levothyroxine. Extra monitoring may be part of the recommended clinical practice.

How to Store and Dispose of Cyclo Progynova

Storage Requirements

Cyclo-Progynova tablets must be stored at a temperature below 30°C and should be kept in a cool, dry place. Regulatory documents require the medicine to be protected from heat, moisture, and direct sunlight. To maintain the integrity of the active ingredients, the tablets must remain in the original package until the time of use.

Stability and Safety

Do not use the medicine after the labeled expiry date or if the tablets show signs of deterioration. A mandatory requirement is to keep the product out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Cyclo-Progynova must not be disposed of in household rubbish or wastewater. The official procedure is to return the product to a pharmacist for proper disposal, which helps ensure environmental protection.